MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) will share updates on its growing portfolio of noninvasive mental health treatments during a fireside chat at the Piper Sandler 37th Annual Healthcare Conference, the company announced. The discussion is scheduled for 12:30 p.m. ET on Dec. 4, 2025, and will be available to registered attendees through the conference portal.
Neuronetics, a global neuroscience company, develops technology-driven alternatives for patients who have not benefited from traditional medications. Its flagship treatment, NeuroStar Advanced Therapy, is a non-drug, noninvasive transcranial magnetic stimulation (TMS) system used to treat major depressive disorder and other neuropsychiatric conditions. The company also operates Greenbrook TMS treatment centers nationwide, offering both NeuroStar and SPRAVATO nasal spray for treatment-resistant depression.
NeuroStar remains the most widely used TMS system for depression in the United States, backed by the industry’s largest clinical data set and more than 7.4 million treatments delivered. Greenbrook centers have provided over 1.8 million additional treatments to more than 55,000 patients.
The therapy is FDA-cleared for adults with major depressive disorder, as an adjunct treatment for obsessive-compulsive disorder, for anxiety symptoms associated with MDD, and as a first-line adjunctive treatment for adolescents aged 15 to 21 with MDD.
The appearance at Piper Sandler’s conference will allow Neuronetics’ leadership to outline market trends, clinical progress and expansion opportunities as demand grows for alternative mental health treatments.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.